Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I/II PaedNEO-VAX trial of PTX 108 for Brain tumour (In children, In adolescents, Late-stage disease, Second-line therapy or greater) in Australia

Next Previous
Trial Profile

A phase I/II PaedNEO-VAX trial of PTX 108 for Brain tumour (In children, In adolescents, Late-stage disease, Second-line therapy or greater) in Australia

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 16 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PTX 108 (Primary)
  • Indications Brain cancer; Ependymoma; Glioma; Medulloblastoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PaedNEO-VAX

Most Recent Events

  • 16 Feb 2026 New trial record
  • 04 Feb 2026 According to Providence Therapeutics media release, the trial will begin in March 2026 across seven pediatric hospitals in Queensland, South Australia, New South Wales, Victoria, and Western Australia. It is sponsored by the Australia & New Zealand Children's Haematology and Oncology Group (ANZCHOG).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top